Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

4.80USD
11:23am EST
Change (% chg)

$0.05 (+1.05%)
Prev Close
$4.75
Open
$4.69
Day's High
$4.87
Day's Low
$4.69
Volume
5,556
Avg. Vol
41,694
52-wk High
$11.66
52-wk Low
$4.30

Summary

Name Age Since Current Position

Dror Ben-Asher

51 2011 Chairman of the Board, Chief Executive Officer

Micha Ben Chorin

48 2016 Chief Financial Officer

Gilead Raday

42 2016 Chief Operating Officer

Reza Fathi

63 2010 Senior Vice President - Research & Development

Adi Frish

47 2012 Senior Vice President - Business Development and Licensing

Uri Aharon

36 2011 Chief Accounting Officer

Patricia Anderson

2016 Vice President - Regulatory Affairs

Aida Bibliowicz

2016 Vice President - Clinical Affairs Europe

Shani Maurice

2016 Vice President - Business Development & Communications

Danielle Abramson

2016 Director - Intellectual Property & Research

Patricia Bandeira

2016 Product Manager - Oncology

Clara Fehrmann

2016 Director - Clinical Operations

Guy Goldberg

41 2012 Chief Business Officer

Ira Kalfus

2012 Medical Director

Patrick Mclean

Product Manager

Terry Plasse

2016 Medical Director

Shmuel Cabilly

67 2010 Director

Kenneth Reed

63 2009 Director

Rick Scruggs

57 2016 Director

Eric Swenden

73 2010 Director

Ofer Tsimchi

58 2011 Director

Nurit Benjamini

50 2016 External Director

Dan Suesskind

73 2011 External Director

Biographies

Name Description

Dror Ben-Asher

Mr. Dror Ben-Asher serves as Chairman of the Board and Chief Executive Officer at Redhill Biopharma Ltd since May 4, 2011. He has held the roles of Chief Executive Officer and Director at the Company since August 3, 2009. His work experience includes the following roles: Manager at P.C.M.I. Ltd. (an affiliate of ProSeed Capital Holdings CVA, which provides Redhill Biopharma Ltd with certain advisory services) and Director at Agrea Ltd. He holds an LLB degree from University of Leicester, a Masters degree in Law (MJur) from University of Oxford and a Master of Legal Letters degree from Harvard University.

Micha Ben Chorin

Mr. Micha Ben Chorin has been appointed Chief Financial Officer at Redhill Biopharma Ltd effective March 1, 2016. His work experience includes the following roles: Chief Financial Officer at Pyramid Analytics, Director at Discount Investment Corp. Ltd. (November 18, 2014), Vice President - Finance at Aqua Control Systems Ltd (from 2013) and Vice President - Finance at Starhome NV (2009-2013). Mr. Ben Chorin holds a Bachelors degree in Accounting and Economics and a Master of Arts degree, both from Tel Aviv University. He is Certified Chartered Accountant.

Gilead Raday

Mr. Gilead Raday serves as Chief Operating Officer at Redhill Biopharma Ltd. Prior to this, he served as Vice President - Corporate and Product Development at the Company from November 1, 2010. His work experience includes the following roles: Interim Chief Executive Officer of Sepal Pharma Plc. (January 2010-October 2010), Independent Consultant for life sciences, specializing in business development and project management (January 2009-December 2009), Partner at Charles Street Securities Europe, LLP (2004-2008) and Board Member at Sepal Pharma Plc., ViDAC Limited, Morria Biopharmaceuticals Plc., Vaccine Research International Plc., TKsignal Plc. and Miras Medical Imaging Plc. He holds a Master of Science degree in Neurobiology from The Hebrew University of Jerusalem and a Master of Philosophy degree in Biotechnology Management from Cambridge University, UK.

Reza Fathi

Dr. Reza Fathi serves as Senior Vice President - Research & Development at Redhill Biopharma Ltd, effective since May 1, 2010. His work experience includes the following roles: Director of Research in XTL Biopharmaceuticals Inc. (2005-2009), Director of Research at Vivoquest, Inc. (2000-2005), Manager of Chemical Biology Research at the Institute of Chemistry and Chemical Biology (ICCB) at Harvard Medical School (1998-2000) and Head of Discovery Group at PharmaGenics, Inc. (1991-1998). Dr. Fathi holds a Postdoctoral and Ph.D. degree in Chemistry from Rutgers University, New Jersey, USA.

Adi Frish

Mr. Adi Frish serves as Senior Vice President - Business Development and Licensing at Redhill Biopharma Ltd, effective since December 5, 2012. Prior to this, he served as Vice President - Business Development and Licensing at the Company from October 20, 2010. His work experience includes the following roles: Chief Business Development at Medigus Ltd. (2006-2010) and Associate and Partner at the law firm of Y. Ben Dror & Co. (1998-2006). He holds a LLB degree from Essex University and a Master of Legal Letters degree from Bar Ilan University.

Uri Aharon

Mr. Uri Hananel Aharon serves as Chief Accounting Officer at Redhill Biopharma Ltd, effective since 2012. His work experience includes the following roles: Team Manager at Ernst & Young Israel (2007-2011) and Accounting Intern at Ziv Haft, BDO (2004-2007). He holds a Bachelors degree in Accounting and Economics from The Hebrew University of Jerusalem and a MBA degree, majoring in Business Taxation, from the College of Management Academic Studies, Rishon LeZion.

Patricia Anderson

Ms. Patricia Anderson is Vice President - Regulatory Affairs of the Company. Patricia Anderson has over 30 years of experience in regulatory affairs, developing numerous successful submissions to regulatory agencies across North America and Europe. Prior to joining RedHill, Ms. Anderson served as VP of Regulatory Services at MAPI SRS and as a member of the Executive Steering Committee for SRS, responsible for the business unit for regulatory consulting. She also served in various regulatory affairs positions at PharmApprove International Regulatory Consultants, Hyal Pharmaceutical Corporation and Bayer Canada. Ms. Anderson graduated with a B.Sc. in Biology from York University and received a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society. Ms. Anderson was also honored as a Fellow of the Regulatory Affairs Professional Society.

Aida Bibliowicz

Ms. Aida Bibliowicz is Vice President - Clinical Affairs Europe of the Company. Ms. Bibliowicz has wide-ranging experience in drug development and clinical development international programs. Prior to joining RedHill Ms. Bibliowicz worked as Director, Project Management and Regulatory Affairs at Cato Research Israel, overseeing large multinational clinical studies in various indications. Ms. Bibliowicz holds a M.Sc. in Quality Assurance and Reliability from the Israel Institute of Technology, Technion, and an MBA from the Tel Aviv University.

Shani Maurice

Ms. Shani Maurice is Vice President - Business Development & Communications of the Company. Shani Maurice previously served as a Project Manager and as a Research Analyst at the Prime Minister’s Office, leading technological projects. She is a graduate of the Hebrew University of Jerusalem (B.Sc. in Biology and Business Administration).

Danielle Abramson

Ms. Danielle T. Abramson, Ph.D. is Director - Intellectual Property & Research of the Company. Danielle Abramson has extensive experience developing, analyzing, and managing intellectual property portfolios for Life Sciences and Medical Device companies. Ms. Abramson received her Bachelor of Science in Mechanical Engineering from Binghamton University and her Doctor of Philosophy in Medical Sciences from Brown University. Danielle Abramson is registered to practice as a patent agent before the U.S. Patent and Trademark Office. Prior to joining RedHill, Ms. Abramson practiced patent law at the international law firm of Greenberg Traurig.

Patricia Bandeira

Ms. Patricia Bandeira is Product Manager - Oncology of the Company. Patricia Bandeira has bench to market experience in the pharmaceutical sector acquired through work in biotech, contract research and large pharma. Patricia served in Operations Management and Project Management at both Merck Canada, Inc. and Schering Plough Canada, Inc. She is a graduate of McGill University (B.Sc. in Biochemistry, minor in Biotechnology) and the John Molson School of Business of Concordia University (MBA).

Clara Fehrmann

Ms. Clara Fehrmann serves as Director - Clinical Operations of Redhill Biopharma Ltd. She has R&D experience in the pharmaceutical industry acquired across pharma, biotech as well as contract research companies. Prior to joining the Company, she served as Clinical Project Manager at Merck Canada, Inc. and in various drug development positions at Santhera Pharmaceuticals. She has also served as Clinical Research Associate at ICON Clinical Research (Canada), Inc. Ms. Fehrmann graduated with a B.Sc. in Microbiology and Immunology from McGill University in Montreal and holds an M.Sc. degree in Pharmaceuticals from the University of Montreal, Canada.

Guy Goldberg

Mr. Guy Goldberg serves as Chief Business Officer at Redhill Biopharma Ltd since July 16, 2012. His work experience includes the following roles: Vice President Vice President of Business Operations at Eagle Pharmaceuticals, Senior Vice President of Business Operations at Eagle Pharmaceuticals, New Jersey, Associate at ProQuest Investments (2004-2007) and Consultant at McKinsey & Company (2002-2004). He holds a Bachelor of Arts degree in Economics and Philosophy from Yale University and a Juris Doctor degree from Harvard School of Law.

Ira Kalfus

Dr. Ira N. Kalfus, M.D. serves as Medical Director of Redhill Biopharma Ltd. Prior to joining RedHill, Ira was with Lev Pharmaceuticals (VP of Medical Affairs), Aetna/US Healthcare, Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). He completed residency in Internal Medicine at LIJ and graduated from the Albert Einstein College of Medicine (M.D.) and Columbia University (B.A. in Biology).

Patrick Mclean

Mr. Patrick Laughlin Mclean serves as Product Manager at Redhill Biopharma Ltd. He accumulated experience in various senior executive positions in pharmaceutical companies including Giaconda Limited (CEO and Acting Chairman), Axcan Pharma (Senior VP European Commercial Operations, VP Sales & Marketing, Canada & US), Cossette Health Group (General Manager) and Allard Pharma Communications (President). Mr. Mclean graduated from the University of Minnesota (B.S. Chemistry).

Terry Plasse

Dr. Terry F. Plasse, M.D. is Medical Director of the Company. Dr. Plasse has extensive experience in drug development, primarily in oncology, having worked with several large as well as small pharmaceutical and biotech firms. He was previously Director for Oncology for North America at Rhone-Poulenc Rorer and served as a consultant to several major firms, including Chiron, Merck and Bristol-Myers Squibb. Dr. Plasse completed his fellowship in medical oncology at Mt Sinai Medical Center and his medical residency at Beth Israel Hospital, both in New York. He is a graduate of the Washington University School of Medicine, St. Louis, and received his BA from Brandeis University, in Waltham, MA.

Shmuel Cabilly

Dr. Shmuel Cabilly serves as Director at Redhill Biopharma Ltd, effective from August 26, 2010. He is a scientist. Previously, he worked for several companies, including Ethrog Biotech (Co-Founder and Chief Scientist) that was sold to Invitrogen. He graduated from The Hebrew University of Jerusalem (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production. Dr. Cabilly also holds a Bachelor of Science degree in Biology from Ben Gurion University and a Master of Science degree in Microbiology from The Hebrew University of Jerusalem.

Kenneth Reed

Dr. Kenneth Reed serves as Director of Redhill Biopharma Ltd, effective from December 15, 2009. Dr. Reed is a dermatologist, practicing in a private practice. He also serves as Director at Minerva Biotechnologies Corporation. Dr. Reed holds a Bachelors degree from Brown University, a Doctorate of Medicine degree from the University of Medicine and Dentistry of New Jersey and has completed the Harvard Medical School Residency Program in Dermatology.

Rick Scruggs

Mr. Rick D. Scruggs serves as Director at Redhill Biopharma Ltd since January 1, 2016. Mr. Scruggs most recently served as Executive Vice President of Business Development at Salix until its acquisition by Valeant in March 2015. Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals, and helped build Salix’s commercial organization, serving in various sales and commercial trade related positions. He was appointed as Executive Vice President in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix innovative products and intellectual property. Mr. Scruggs also served as the Head of the board of directors of Oceana Therapeutics, Salix’s European subsidiary. Mr. Scruggs holds a B.S. in Criminal Justice from the Appalachian State University in North Carolina.

Eric Swenden

Mr. Eric Swenden serves as Director at Redhill Biopharma Ltd, effective from May 3, 2010. He is a member of the investment committee since May 5, 2011. His work experience includes the following roles: Chief Executive Officer (from1985) and Executive Chairman (from 1990) at Vandemoortele Food Group, Belgium, and Director at Lifeline Scientific, Inc., TBC S.A., Alterpharma N.V. and Gudrun N.V. He holds a Masters degree in Commercial Science from the Universiteit Antwerpen.

Ofer Tsimchi

Mr. Ofer Tsimchi serves as Director at Redhill Biopharma Ltd since May 4, 2011. From 2008 to 2012, Mr. Tsimchi served as the Chairman of the board of directors of Polysack Plastic Industries Ltd. and Polysack-Agriculture Products, and since 2006, he has served as a Partner in the Danbar Group Ltd., a holding company. Mr. Tsimchi currently serves on the board of directors of Kidron Industrial Materials Ltd., Amutat Zionut 2000, Danbar Group Ltd, and Polysack Agriculture Hi-Technologies, CaesarStone Sdot-Yam Ltd. and Maabarot Products Ltd. Mr. Tsimchi received his BA in Economics and Agriculture from the Hebrew University of Jerusalem, Israel. The board of directors has determined that Mr. Tsimchi is a financial and accounting expert under Israeli law.

Nurit Benjamini

Ms. Nurit Benjamini serves as External Director at Redhill Biopharma Ltd since February 16, 2016. She is a member of the audit and compensation committees. Her work experience includes the following roles: Chief Financial Officer at TabTale Ltd. (from December 2013), Chief Financial Officer at Wixpress Ltd. (2011-2013), Chief Financial Officer at CopperGate Communications Ltd. (now Sigma Designs Israel; 2007-2011), Chief Financial Officer at Compugen Ltd. (2000-2007), Chief Financial Officer at Aladdin Knowledge Systems Ltd. (1993-1998), External Director at BiolineRx Ltd. and Director at Allot Communications Ltd. She holds a Bachelors degree in Business and Economics and a MBA degree, majoring in Finance, both from Bar Ilan University.

Dan Suesskind

Mr. Dan S. Suesskind serves as External Director at Redhill Biopharma Ltd, effective from February 21, 2011. He is a member of the audit, financial statements and investment committees since May 5, 2011. His work experience includes the following roles: Chief Financial Officer at Teva Pharmaceutical Industries Ltd. and Member of the Boards of Directors at Migdal Insurance Company, Ness Technologies Ltd and Syneron Medical Ltd. Mr. Suesskind holds a Bachelors degree in Economics and Political Science from The Hebrew University of Jerusalem and a MBA degree from University of Massachusetts, USA. Mr. Suesskind is a member of the Israeli Forum of Chief Financial Officers and was awarded the “Life Time Achievement Award” from that forum in 2007.